BMP32r of 41 aas and 1 N-terminal TMS.  Recombinant bacteriocin BMP32 (BMP32r) prepared by the Escherichia coli expression system had a broad-spectrum antibacterial activity even against some MDR bacteria and its minimal inhibitory concentration ranged from 9.2 to 36.8 mg/L.  BMP32r showed good stable performance in heat, pH and storage. Scanning electron microscopy and transmission electron microscopy revealed that BMP32r killed indicator strains through cell wall destruction, pore formation, and the membrane permeability increases. The wound healing of an animal MDR S. aureus infected model was promoted by BMP32r, and the safety was verified by the cytotoxicity assay that the viability of HFF cells remained 87.3%, even when the concentration of BMP32r was as high as 147.2 mg/L. No abnormalities or damages to major organs was found in vivo assessments after treatment with BMP32r. Thus, BMP32r may be developed as a safe antimicrobial agent to treat MDR bacterial infections (Qiao et al. 2020).